Stay updated on PAAP for Pralsetinib in NSCLC and MTC Clinical Trial
Sign up to get notified when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.

Latest updates to the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe record now presents details for the pralsetinib pre-approval access program for patients with unresectable or metastatic NSCLC, medullary thyroid cancer, or certain other RET-altered tumors. It includes eligibility requirements, dosing information, expanded-access status, and study record dates.SummaryDifference26%

- Check20 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide NIH notice about updates to terminology appears above the unchanged 403 error message.SummaryDifference1%

- Check34 days agoChange DetectedThe footer revision number changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer’s site revision identifier advances from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check62 days agoChange DetectedThe study page now displays a 403 Forbidden error instead of the expected study content, indicating restricted access to the NCT04204928 record and a generic access-denied page is shown.SummaryDifference14%

Stay in the know with updates to PAAP for Pralsetinib in NSCLC and MTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.